Avanir Pharmaceuticals, Inc.

Otsuka Pharmaceutical Co. Ltd. has now decided to fully terminate the development of its neuropsychiatric compound AVP-786 following a Phase III failure reported earlier this year. The decision is in

H. Lundbeck A/S / Otsuka Pharmaceutical Co. Ltd. ’s and Axsome Therapeutics, Inc. ’ respective Alzheimer’s disease agitation drug candidates, Rexulti and Auvelity, have both hit the bullseye in their

In positive new top-line Phase III results in the CNS space, Otsuka Pharmaceutical Co. Ltd. said its oral serotonin-norepinephrine-dopamine triple re-uptake inhibitor centanafadine hit its primary e

For biopharma companies, the past decade was filled with momentous events in the legal realm, from creation of a new way to challenge patents to the emergence of biosimilar litigation and generic pric